Reference : Le medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec)
Scientific journals : Article
Human health sciences : Urology & nephrology
Human health sciences : Endocrinology, metabolism & nutrition
Le medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec)
[en] The drug of the month: Olmesartan medoxomil
Krzesinski, Jean-Marie mailto [Université de Liège - ULiège > Département des sciences cliniques > Néphrologie >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
Hopital de Baviere
Yes (verified by ORBi)
[en] Hypertension ; Olmesartan ; Angiotensin II AT1 receptor blocker
[fr] Hypertension artérielle ; Olmésartan ; Récepteur AT1 de l'angiotensine II
[en] Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of hypertension. Olmesartan is indeed an antihypertensive agent with an efficacy dependent on the dose from 10 to 40 mg. It is taken once a day, because of a long duration of action. This prodrug has a dual elimination pathway (biliary and renal). The contraindications are the same as for the other sartans. One of its main advantage, besides its rapidly observed efficacy to lower high blood pressure, is its relatively low cost within this family. It has also cardiovascular and renal protective effects. The recommended usual dosage is 20 mg/day.
Researchers ; Professionals ; Students ; General public

File(s) associated to this reference

Fulltext file(s):

Open access
Olmésartan Médoxomil (Belsar ou Olmetec).pdfPublisher postprint629.2 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.